JPRN-UMIN000048277已完成未知
Renal protective effects of tofogliflozin and changes in clinical parameters affecting renal function in patients with type 2 diabetes - Renoprotective effect of tofogliflozin
Department of Diabetes, Metabolism and Kidney Disease, Edogawa Hospital0 个研究点目标入组 158 人开始时间: 2022年7月5日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 158
研究概览
简要总结
The BW, BP, UP and serum UA decreased from baseline in both eGFR groups while the Hb increased. The eGFR did not significantly differ over time. The change in the eGFR at 12 months after the initiation of tofogliflozin was -1.9 and 0.2 mL/min/1.73 m2 in the normal- and low-eGFR group, respectively. In the normal-eGFR group, the change in the eGFR showed a significant negative correlation with the HbA1c and eGFR at baseline.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Tofogliflozin had already administered at the initial consultation 2. Patients who discontinued treatment or who were transferred to other hospitals during the observation period 3. Patient after renal transplantation 4. Iron preparations were started during the observation period 5. GLP-1 receptor agonists were started during the observation period 6. Antihypertensive agents, diuretics or urate lowering agents were changed during the observation period
研究者
相似试验
已完成
不适用
The protective effect of canagliflozin on renal function in obese patients with T2DMObese T2DM with nephropathyJPRN-UMIN000018711Division of Nephrology, Nippon Medical School20
已完成
不适用
Tofogliflozin And Empagliflozin Cross-over TrIal(TACTICS)JPRN-jRCTs031190021Yamada Yoshihiko56
Unknown
不适用
Antidiuretic Function Before and During Treatment With SGLT2 InhibitorsArterial HypertensionBody Weight ChangesDiabetes Mellitus, Type 2NCT03917758University of Turin, Italy30
已完成
不适用
Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease (NAFLD) patients with type 2 diabetes. Randomized, open label pilot study.on-alcoholic fatty liver disease (NAFLD) with type 2 diabetesJPRN-UMIN000030355Yokohama City University40
已完成
不适用
Effect of tofogliflozin and pioglitazone on hepatic steatosis in NAFLD patients with type 2 diabetes.Type 2 Diabetes, NAFLDDiabetes, NAFLDJPRN-jRCTs031180159Yoneda Masato40